1. Scrip
  2. >>Business
  3. >>Financing

Antibody-Drug Conjugates Attract Hefty Funding To ADC Therapeutics

 
• By John Davis

Swiss oncology company ADC Therapeutics, which has just added another $200m to its coffers, is developing a new class of antibody-drug conjugates that may be less visible to DNA repair mechanisms and therefore less susceptible to the development of resistance than other anticancers.

Chris Martin of ADC Therapeutics
Chris Martin, CEO of ADC Therapeutics • Source: ADC Therapeutics

Having a realistic view of the amount of funding required to take a potential medicine through clinical trials could be thought a prime requirement of a biotech company, one being exhibited by Lausanne, Switzerland-based biotech ADC Therapeutics SARL, that has just raised $200m to take two of its novel antibody-drug conjugate anticancers into and through registrational clinical trials.

The financing is one of the largest private fundraisings for a European biotech over the past couple of years, and...

More from Financing

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.